What factors should influence the dosage and interval of prophylactic treatment in patients with severe haemophilia A and B?
Petrini P. Petrini P.
. Marconi VC, et al. Lancet Respir Med. 2021 Aug 31:S2213-2600(21)00331-3. doi: 10.1016/S2213-2600(21)00331-3. Online ahead of print. Lancet Respir Med. 2021. PMID: 34480861
.
![top](data:image/svg+xml,%3Csvg%20xmlns="http://www.w3.org/2000/svg"%20width="16"%20height="16"%3E%3Crect%20fill-opacity="0"/%3E%3C/svg%3E "top")